Product Pipeline
Product Indication(s) Status Marketing Rights
Indiplon Insomnia May 16, 2006: Neurocrine announced receipt of FDA approvable letter for 5 mg and 10 mg capsules and FDA non-approvable letter for 15 mg tablets; Review ongoing1 Neurocrine
Bicifadine Pain Phase III DOV
DOV 21,947 Depression Phase Ib/Phase II planned Merck/DOV
DOV 102,677 Alcohol Abuse/Alcoholism Phase Ib Planned DOV
DOV 216,303 Indications other than Depression, Anxiety and Addiction Preclinical/Phase II2 DOV
DOV Diltiazem Angina and Hypertension Phase I/Phase III planned for 20073 DOV
DOV 216,303 Depression, Anxiety and Addiction 4 Merck/DOV

1. According to Neurocrine's public disclosures as of June 22, 2006.

2. Although we have completed a Phase II with DOV 216,303 in depressed patients, we are currently evaluating it in preclinical models to determine the next retained indication, if any, other than indications licensed by Merck, that we will pursue in clinical development. Merck has licensed the rights to depression, anxiety and addiction.

3. In July 2004, we reached agreement with the FDA on the scope and design of the clinical trials required for submission of an NDA for DOV diltiazem; we are seeking a partner for final development and commercialization.

4. Our sublicensee for DOV 216,303, Merck, has elected not to authorize disclosure of its development plans.